CES 2022: Abbott CEO Robert Ford Announces New Biowearables Line For Consumers, Paving The Way From Measuring Glucose To Ketone, Lactate, Alcohol
Abbott announced today at CES 2022 it is developing a new line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year.
You may also be interested in...
Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.
Medtech Insight caught up with Abbott’s division VP of Lingo Biowearables at HLTH to learn more about its recent UK launch and future plans.
Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.